Pulmonx Corporation, the company behind a minimally invasive treatment for severe COPD and emphysema, has raised $66.0M in Series d funding.
The company's flagship product, the Zephyr Endobronchial Valve, offers a one-time bronchoscopic procedure. During the treatment, tiny valves are placed in the airways to block off diseased parts of the lung, allowing trapped air to escape and healthier sections to expand. This process helps patients breathe easier and reduces shortness of breath.











.png&w=3840&q=75)


.png&w=3840&q=75)
